In an article titled “Reslizumab performance tied to eosinophil count,” published October 17, 2016, the frequency of infusions was misstated. Study participants were randomized to infusions of reslizumab 3.0 mg/kg or placebo given once every 4 weeks for 16 weeks.
FROM THE JOURNAL OF DRUGS IN DERMATOLOGY Patients with actinic keratosis who used UPF ...
FROM MMWR Nearly 1 million visits to physicians’ offices, outpatient clinics, and emergency departments ...
More than 80% of measles cases reported in the United States in 2015 were ...
